New medicines, devices, and diagnostics produced by the life sciences community in California are giving clinicians better tools to fight disease and improve quality of life for patients around the world. CLSA President & CEO Mike Guerra pens an op-ed in Xconomy on the strength and growth of California’s life sciences sector.
Assemblyman Rob Bonta, Co-Chair of the California Legislative Rare Disease Caucus, pens an op-ed in The Sacramento Bee on the need to raise awareness and help California develop strong public policies to streamline the drug development pipeline and ensure that everyone with a rare disease gets the treatment they deserve.
Assembly Bill 375, the California Consumer Privacy Act, will require companies that store large amounts of data, such as Google, Facebook, Twitter, and others, to disclose what kinds of data they collect, and give consumers more control over how that data is shared.
CLSA Board Member David Beier pens an op-ed in STAT News regarding the impact of the 2.3% medical device tax on patient care and innovation.
CLSA President & CEO Sara Radcliffe pens an op-ed in the San Diego Business Journal regarding the need to nurture California and San Diego’s innovative life sciences industry.
Sara Radcliffe, Pres. & CEO, CLSA & Don Bobo, Corporate Vice President, Strategy & Corporate Development, Edwards Lifesciences, pen an op-ed in The O.C. Register, urging Congress repeal the 2.3% medical device tax. The tax stands to threaten an innovative medtech sector that employs over 22,000 in Orange County and 77,200 statewide.
“Californians have legitimate concerns about access to affordable drugs, but SB 17 does not address them. It is a bad deal for business and does nothing to benefit patients.” – William J. Newell, CEO, Sutro Biopharma & Vice Chairman, California Life Sciences Association.
“As an early-stage company CEO, I’m afraid that SB 17 will increase uncertainty and stifle investment that companies like ours rely on to develop new drugs.”
“Cancer is frightening in the abstract, and even more so when it becomes your reality. Three years ago, I was diagnosed at a relatively young age with late-stage colon cancer and have since gone through extensive treatments.”
CLSA President & CEO Sara Radcliffe pens a letter to the editor of The Sacramento Bee, responding to an op-ed by Sen. Ed Hernandez on SB 17, a bill being deceptively sold under the label of drug pricing transparency.
CLSA Pres. & CEO Sara Radcliffe pens an op-ed in The San Diego Union-Tribune on the strength of California and San Diego’s life sciences industry, the importance of BIO 2017 coming to San Diego, importance of policymakers and stakeholders to sustain and nurture growth of the sector.
CLSA Pres. & CEO Sara Radcliffe pens an op-ed in the Los Angeles Daily News outlining the strength of California life sciences industry, and calling on policymakers and stakeholders to sustain and nurture its growth.
CLSA Pres. & CEO Sara Radcliffe pens an op-ed in the San Jose Mercury News calling on Congress to repeal the Independent Payment Advisory Board (IPAB), a controversial advisory board enacted as part of the ACA, which threatens seniors’ care and could harm biomedical innovation by reducing incentives for investment in new research and product development.
CLSA’s Jenny Carey and EveryLife Foundation for Rare Diseases’ Julia Jenkins pen an op-ed in The Hill on the need enact sound public policies that help tackle the more than 7,000 rare diseases affecting 30 million people, more than half of whom are children.
CLSA Pres. & CEO Sara Radcliffe pens a letter to the editor of The Sacramento Bee responding to their Aug. 11 editorial endorsement of SB 1010, flawed legislation that could enable speculative buying of medicines, creating shortages and leading to growth in “gray markets” where medicine is sold to the highest bidder.
Caroline Loewy, a mother and parent advocate for rare diseases, pens an op-ed in the East Bay Times calling on the policymakers to invest in and promote medical innovation.
CLSA Pres. & CEO Sara Radcliffe pens an op-ed in The Sacramento Bee on the pitfalls of SB 1010, flawed legislation that could hinder patient access to care in California.
Dr. R. Swamy Venturupalli, a former Clinical Chief of Rheumatology at Cedars Sinai Medical Center and a leader in the field of genetic and molecular causes of autoimmune diseases, pens an op-ed in The Fresno Bee highlighting the need to be aware of the potential and unintended consequences when it comes to healthcare decisions, including protecting patients, encouraging innovation and ensuring life-saving medications are available to all who need them.
CLSA Pres. & CEO Sara Radcliffe pens a letter to the editor of the Los Angeles Times, highlighting the flaws of SB 1010, which creates additional red tape and leads to gray-market prescription drug stockpiling.
Bridget Hood, a patient advocate, pens an op-ed in The Orange County Register calling on elected officials in Sacramento and Washington D.C. to not make any kinds of policy decisions that could weaken access or slow down medical innovation, but instead, help turn the hope for miracle medicines into a reality by moving medical innovation forward.
CLSA’s own Eve Bukowski, our VP of State Government Relations and a cancer fighter pens a letter to the editor of CALMatters, which pushes back on a recent article in CALMatters (“California Searches for Prescription to Treat Rising Drug Costs,” April 10) that suggests the state simply could not afford to treat poor patients who need life-saving medicines to treat their serious or even life-threatening illness.
A Letter to the Editor authored by CLSA President & CEO Sara Radcliffe was published in the Los Angeles Daily News. This letter responds to an opinion piece originally published February 18 by Heidi Sanborn, executive director of the California Product Stewardship Council, a key group pushing the local takeback initiatives in California.
CLSA’s Jenny Carey and EveryLife Foundation for Rare Diseases’ Julia Jenkins pen an op-ed in The Hill on the need to tackle the more than 7,000 rare diseases that affect nearly 30 million people.
In a Sacramento Bee op-ed, CLSA Pres. & CEO Sara Radcliffe warns California State Lawmakers to be wary of misguided proposals that claim to provide transparency, yet in reality only create hurdles to bringing drugs to market, slowing or reversing years of progress.
CLSA Pres. & CEO Sara Radcliffe pens an op-ed in the San Diego Union-Tribune regarding the need to protect and nurture California’s life sciences innovation economy.
Bill Hirsh, Executive Director of the AIDS Legal Referral Panel, pens an op-ed in the San Francisco Examiner on the need for insurance companies to stop practices that limit access to innovative medicines.
Kristin Todd, a young mom and wife, provides guest commentary in an opinion piece for The Sacramento Bee regarding her ongoing battle with breast cancer while navigating the red-tape of the insurance system, working full-time and being a new parent.
Janet Klein provides guest commentary in an opinion piece for the Los Angeles Daily News entitled “Put Patients Ahead of Profits in Health Care Decisions”. Klein –a contributor to CLSA’s “Value of Innovation” campaign – discusses her personal fight with Stage 4 breast cancer, the innovative therapies that saved her life, and the importance of continuing to invest in research and development of ground-breaking medicines.
Carol Cox, a member of the California Life Sciences Association (CLSA) board of directors and executive vice president of NuVasive, pens an op-ed in the San Diego Business Journal on the medical technology revolution taking place in Southern California.
CLSA Pres. & CEO Sara Radcliffe pens an op-ed in the Sacramento Business Journal calling on California lawmakers to work to prevent and eliminate discriminatory practices by insurance companies and health plans that limit access to care in California.
CLSA President & CEO Sara Radcliffe makes the case in this San Jose Mercury News op-ed on how California should value innovation in life sciences.
CLSA President & CEO Sara Radcliffe pens an op-ed in The Sacramento Bee regarding H.R. 9, federal legislation that would weaken the process that turns research into products, new companies.
Paul Hastings, CLSA Board Member and OncoMed Pharmaceuticals Chairman & CEO, pens an op-ed in the San Francisco Business Times calling on Congress to safeguard and preserve our patent system. Failure to do so would be be a blow to our role as the world’s leader in life sciences innovation.
CLSA President & CEO Sara Radcliffe pens an exclusive op-ed in Roll Call applauding the 21st Century Cures Act. This landmark package of legislation includes a series of improvements to the healthcare system that will improve the lives of millions around the world, by accelerating the pace of drug, device and diagnostics discovery and development.
Todd Gillenwater, CLSA’s Executive Vice President – Advocacy & External Relations, pens an op-ed in The Hill calling on Congress to protect FDA user fees from sequestration.
Insurance practices create barriers to life-saving medications, undermine effective health care By Sara Radcliffe, Op-Ed Special to The Sacramento Bee March 29, 2015 Every day advances in medical innovation saves lives. Patients who just a few years ago might have died from cancer, heart disease or HIV/AIDS can turn the page and continue productive lives. … Continue reading Sacramento Bee: Opinion: Insurance practices create barriers to life-saving medications, undermine effective health
In the United States, protecting intellectual property is a bedrock principle. Without clear patent processes and strong enforcement rights, markets everywhere would be crippled by uncertainty. Investors could never be confident that companies actually own the innovations they are working to commercialize.
When the medical device tax was first proposed to help fund the Affordable Care Act (ACA), many people in government and the life sciences community expressed misgivings over its possible negative consequences. Unfortunately, those concerns have been substantiated by real-world experience. Since its implementation in 2013, this 2.3 percent excise tax has cost jobs, stifled innovation and will ultimately reduce access to lifesaving devices.
CLSA’s Todd Gillenwater pens an op-ed for The Sacramento Bee. California has been associated with risk-taking, entrepreneurship and innovation since the Gold Rush. Today, California is still an innovation engine in such varied sectors as agriculture and the Internet. But only one homegrown industry can stake a claim as a leading contributor to our state’s economy and the health of people around the world: the life sciences sector.
In 2012, following years of concern over U.S. Food and Drug Administration (FDA) medical device review processes that were viewed as increasingly unpredictable and inefficient, plaguing investment, innovation and U.S. competitiveness, stakeholders including Congress, the Agency and the medical device industry worked to identify potential solutions. The shared goal: to improve product review times while also maintaining rigorous scientific and patient safety standards.
The Centers for Disease Control and Prevention (CDC) estimates that more than one-third of adults in the United States are obese. A 2012 study published by the Journal of Health Economics found that the economic costs of obesity are tremendous, with Americans spending over $190 billion each year on obesity-related medical expenses. These costs go far beyond direct healthcare spending, as obesity contributes to short-term work absences, long-term disability, and premature death.
Most patients with chronic health conditions rely on prescription medications as the primary method for treating their disease. In fact, eight out of ten of all health conditions are now treated with prescription medications. An alarming number of patients, however, do not take their medications as prescribed, leading to deteriorating health and expensive hospital stays and urgent care visits, which costs the health care system nearly $300 billion dollars every year.
Todd E. Gillenwater, CLSA’s Executive Vice President of Advocacy & External Relations pens a letter to the editor of the San Francisco Chronicle on the value of medical innovation.
Hepatitis C affects 3.2 million Americans, resulting in more than 16,000 deaths annually. It’s the leading cause of liver cancer and liver transplants, which require major surgery and hospitalization. Early therapies for the condition required weekly injections that caused side effects such as anemia, depression and flu-like symptoms, leading many to stop treatment.
This past week, as more than 250 families walked the halls of Congress sharing their personal stories and advocating for policies that protect patients and bolster innovation for therapies that treat rare diseases (conditions affecting 200,000 people or less), they received a surprising message that irreparable harm may be caused to their efforts.
Among the harms resulting from sequestration and the recent government shutdown, it’s hard to imagine anything worse than the damage to our National Institutes of Health (NIH). For generations, this federal agency has been the world leader in funding medical research.
Imagine an industry constructively working with a government agency for nearly two years to identify needed improvements to its processes to better serve Americans. Now, imagine the industry offering to help pay for the improvements. And, finally, in today’s hyper-partisan atmosphere, imagine Congress voting, with overwhelming support from Republicans and Democrats alike, to pass that agreement into law. A case study in how D.C. should work, right? Well‚Ä¶ not so fast.
Here in California, the birth of the biotechnology industry was fueled by federal funding through the National Institutes of Health. Across the country, this funding helped lead to the development of medicines that treat millions of people worldwide.